Quantcast

Latest PolyMedix Inc. Stories

2011-01-13 00:00:41

As the first step in PolyMedix's US clinical development activities with PMX-30063, it has initiated a Phase 1 clinical trial. (Vocus/PRWEB) January 12, 2011 Last November, PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, received regulatory clearance from the FDA to investigate its new antibiotic candidate, PMX-30063. PMX-30063 was inspired by a key discovery: It is possible to...

2010-04-05 13:00:00

RADNOR, Pa., April 5 /PRNewswire-FirstCall/ -- Polymedix Inc announces the following Webcast: What: PMX-30063 Phase 1B Clinical Study Results When: April 6, 2010 @ 10:00 AM Eastern Where: http://www.investorcalendar.com/ClientPage.asp?ID=156938 Live over the Internet --Simply log on to the web at the How: address above. Contact: Lisa Caperelli, 484.598.2406, lcaperelli@polymedix.com If you are unable to participate...

2009-11-17 15:25:00

SAN FRANCISCO, Nov. 17 /PRNewswire-FirstCall/ -- Merriman Curhan Ford Group, Inc. (Nasdaq: MERR) acted as lead placement agent in PolyMedix Inc.'s (OTC Bulletin Board: PYMX) $20.7 million registered public offering of 20.7 million units. The units, which were priced at $1.00 per unit, consist of one share of PolyMedix common stock and one five year warrant to purchase 0.30 of a share of PolyMedix common stock at $1.25 per share. (Logo: http://www.newscom.com/cgi-bin/prnh/20090911/MCFLOGO)...

2008-12-11 12:29:00

KING OF PRUSSIA, Pa., Dec. 11 /PRNewswire/ -- Emerging Growth Equities, Ltd. initiates coverage of PolyMedix Inc. (OTC Bulletin Board: PYMX) with a BUY rating and a $9.00 price target. PolyMedix focuses on developing novel high-value therapeutic drug products for serious, life-threatening acute disorders. The Company's leading clinical development programs include the antibiotic PMX-30063 and the heparin antagonist PMX-60056. Emerging Growth Equities, Ltd., is a specialty brokerage and...

2008-11-07 09:00:24

PolyMedix, Inc. (OTC BB: PYMX), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will present at Rodman & Renshaw's Tenth Annual Global Healthcare Conference taking place November 10-12, 2008, at the New York Palace Hotel. Nicholas Landekic, President & C.E.O. of PolyMedix, will give the Company presentation on Monday, November 10 at 5:45 PM (EST) in the Louis Room. Additional information...

2008-10-27 18:00:26

PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, will make a total of four presentations of pre-clinical data on its antibiotic compounds at the Interscience Conference on Antimicrobial Agents and Chemotherapy. The conference, held on behalf of the American Society for Microbiology (ASM) and the Infectious Diseases Society of America (IDSA), is...

2008-09-29 12:00:14

PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care products for infectious diseases and acute cardiovascular disorders based on biomimetics, presented new data at the "New Directions in AIDS Treatment Research Policy and Care Symposium" in New York on September 26th, 2008. Pre-clinical in vitro data describing the activity of a variety of PolyMedix's novel small molecule defensin mimetic antibiotic compounds against Mycobacterium...

2008-09-24 09:00:49

PolyMedix Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing acute care therapeutic drug products for infectious diseases and cardiovascular disorders, announced today that it has completed a $4.25 million private placement of preferred stock units. Each unit was priced at $7.00 and consisted of one share of PolyMedix convertible preferred stock and a five year warrant initially exercisable for one share of PolyMedix convertible preferred stock at $10.00...

2008-09-23 09:00:15

PolyMedix, Inc. (OTC BB: PYMX, http://polymedix.com), an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a Phase I clinical study in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA). PMX-60056 represents an entirely new class of drug,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related